Adalimumab: all 321 studies that test it

Page 3 of 4. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.

• ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)CompletedNCT04154852Phase 2
• Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.TerminatedNCT04131322Phase 4
• Comparison of PK and Tolerability of MSB11022 Administered by AI or PFSCompletedNCT04018599Phase 1
• PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)CompletedNCT03983876Phase 1
• Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque PsoriasisCompletedNCT03849404Phase 3
• Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)CompletedNCT03849313Phase 1
• Personalized Therapies in Inflammatory Complex DiseaseCompletedNCT03651518Phase 2
• Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy VolunteersCompletedNCT03579823Phase 1
• Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpACompletedNCT03561649Not applicable
• A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in JapanCompletedNCT03311464Phase 3
• A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy SubjectsCompletedNCT03273192Phase 1
• TDM Guided Early Optimization of ADAL in Crohn's DiseaseActive, not recruitingNCT03261102Not applicable
• Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VIActive, not recruitingNCT03153319Phase 1/2
• Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBDWithdrawnNCT03059849Phase 4
• MSB11022 in Healthy SubjectsCompletedNCT03014947Phase 1
• GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )CompletedNCT02994836Phase 4
• Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"Status unknownNCT02878161Phase 4
• Reduce Risk for Crohn's Disease PatientsCompletedNCT02852694Phase 4
• Treatment Tapering in JIA With Inactive DiseaseCompletedNCT02840175Phase 3
• Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT02762955Phase 3
• MYL-1401A Efficacy and Safety Comparability Study to Humira®CompletedNCT02714322Phase 3
• Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy SubjectsCompletedNCT02675023Phase 1
• Adalimumab in Alleviating Inflammation in Patients With Axial SpondyloarthritisStatus unknownNCT02634541Phase 4
• Diabetes Islet Preservation Immune TreatmentWithdrawnNCT02586831Phase 1/2
• A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid CancersWithdrawnNCT02516774Phase 1
• Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis PatientsCompletedNCT02492217Phase 4
• Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch StudyStatus unknownNCT02489760Phase 4
• Adalimumab PK Bioequivalence Study to EU and US Sourced HumiraCompletedNCT02472912Phase 1
• Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)CompletedNCT02471118Phase 2
• Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) TrialCompletedNCT02256462Phase 4
• Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy SubjectsCompletedNCT02252809Early Phase 1
• A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))CompletedNCT02237729Phase 1
• Pharmacokinetics and Safety Study of LBAL in Healthy SubjectsCompletedNCT02206867Phase 1
• The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) PatientsTerminatedNCT02150473Phase 3
• Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisStatus unknownNCT02132234Phase 4
• Clinical Trial Using Humira in Netherton SyndromeCompletedNCT02113904Phase 2
• Targeted Ultrasound in Rheumatoid ArthritisCompletedNCT02056184Phase 4
• Bone Resorption, Osteoclastogenesis and AdalimumabStatus unknownNCT02035800Phase 4
• Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease PatientsTerminatedNCT01986127Phase 3
• Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint DiseaseCompletedNCT01893996Phase 4
• Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)CompletedNCT01870986Phase 1
• Stopping TNF Alpha Inhibitors in Rheumatoid ArthritisActive, not recruitingNCT01793519Phase 4
• Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With PsoriasisCompletedNCT01722214Phase 4
• Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)WithdrawnNCT01674413Phase 3
• Adalimumab in the Treatment of Chronic PouchitisCompletedNCT01670240Phase 3
• Adalimumab for the Management of Post-operative Crohn's Disease (CD)Status unknownNCT01629628Phase 3
• Doppler Evaluation in RA Patients After Adalimumab.CompletedNCT01609205Phase 4
• Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With ImmunosuppressantsTerminatedNCT01562951Phase 3
• Adalimumab-psoriasis and Small Bowel LesionsCompletedNCT01556672Phase 4
• Efficacy of Humira in Behcet Patients With ArthritisCompletedNCT01497717Phase 3
• Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative ColitisStatus unknownNCT01494857Phase 3
• HUmira in Psoriatic ArthritisCompletedNCT01465438Phase 4
• REstore Working Ability in RheumatoiD ArthritisStatus unknownNCT01405326Phase 4
• Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)CompletedNCT01382160Phase 4
• SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.CompletedNCT01295151Phase 4
• The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.CompletedNCT01270087Phase 4
• Efficacy and Safety of Adalimumab 80 mg Every Other Week With MethotrexateStatus unknownNCT01270035Phase 4
• Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors TherapyStatus unknownNCT01237262Phase 4
• Pain Modulation in Rheumatoid Arthritis (RA) - Influence of AdalimumabCompletedNCT01197144Not applicable
• Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep ApneaCompletedNCT01181570Phase 4
• Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule EndoscopyStatus unknownNCT01144156Not applicable
• Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT01136252Phase 2
• Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With SpondyloarthritisCompletedNCT01029847Phase 4
• Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid ArthritisCompletedNCT01000441Phase 4
• Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel DiseaseWithdrawnNCT00972218Phase 4
• Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT00940862Phase 4
• Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot StudyStatus unknownNCT00855608Phase 1
• To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis SuppurativaCompletedNCT00827996Phase 2
• Bone Resorption, Osteoclastogenesis and AdalimumabCompletedNCT00814866Not applicable
• Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn'sCompletedNCT00736983Phase 3
• Efficacy Study of Humira in the Treatment of Cutaneous SarcoidosisWithdrawnNCT00731757Phase 2
• Safety and Efficacy Study of Humira in Treatment of Pyoderma GangrenosumWithdrawnNCT00730717Phase 2
• Humira in Rheumatoid Arthritis - Do Bone Erosions Heal?CompletedNCT00696059Phase 4
• Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous SarcoidosisWithdrawnNCT00690911Phase 2
• Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumWithdrawnNCT00690846Phase 2
• Adalimumab for Inflammatory OsteoarthritisCompletedNCT00686439Phase 1/2
• Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)CompletedNCT00660647Phase 3
• Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid ArthritisCompletedNCT00650156Phase 1
• Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid ArthritisCompletedNCT00649922Phase 4
• Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With MethotrexateCompletedNCT00647920Phase 3
• A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid ArthritisCompletedNCT00647491Phase 2/3
• Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic ArthritisCompletedNCT00646386Phase 2
• Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00646191Phase 2
• Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug TherapyCompletedNCT00646178Phase 3
• Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00645905Phase 2
• Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00645892Phase 2
• Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00645814Phase 2
• Medical Treatment of Colitis in Patients With Hermansky-Pudlak SyndromeWithdrawnNCT00514982Phase 2
• A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory AsthmaWithdrawnNCT00512863Phase 2
• Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)CompletedNCT00497614Not applicable
• Prospective Study on Intensive Early Rheumatoid Arthritis TreatmentCompletedNCT00480272Phase 4
• An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)CompletedNCT00478660Phase 3
• Danish Multicenter Study of Adalimumab in SpondyloarthritisStatus unknownNCT00477893Phase 4
• Adalimumab in Severe and Acute SciaticaCompletedNCT00470509Phase 2
• A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid ArthritisCompletedNCT00448383Phase 3
• A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)CompletedNCT00427362Phase 3
• Open-Label Adalimumab for Ulcerative Colitis PatientsCompletedNCT00421642Phase 1
• Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)Status unknownNCT00348153Phase 2/3
• Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)CompletedNCT00338650Phase 3
• HECTHOR: Humira to Spare Steroids in Giant Cell ArteritisCompletedNCT00305539Phase 3

← Adalimumab overview